policy impact with FIPRA
Annie joined FIPRA International as a Special Advisor in Healthcare.
Prior to joining FIPRA, Annie worked as a consultant in European government affairs, market access and regulatory affairs for medicinal products, with specific expertise on advanced therapies. Between 2014 and 2020, Annie served as Senior Director, European Public Policy at the Alliance for Regenerative Medicine.
In the last 10 years, Annie has led different initiatives in the field of advanced therapies. Annie’s advocacy efforts contributed to regulatory improvements for ATMP companies in Belgium and she organised the first European ATMP Investor Day meeting in Brussels. As part of her work at the Alliance for Regenerative Medicine, she has also been involved in numerous activities and contributions to improving the policy environment for ATMP developers in Europe.
Prior to consulting, Annie gathered nearly 30 years of experience across various positions working for several biopharmaceutical companies, including Amgen, Pfizer and GSK. She has been an active member in various industry associations and has led industry initiatives in the areas of Biotechnology and Health Technology Assessment.
Annie holds a Master in Pharmacy (University of Louvain, Belgium) and has been qualified as an industrial pharmacist since 1983. She has lectured in different educational courses for healthcare professionals and students in Belgium. Annie is a Belgian national.
FR - EN - NL